May 23, 2022 7:44am

It's always time to de-risk after HIGHs; keeping a minimal exposure, if not stay on sidelines

What “pops” in the morning session will more than probably fade by the close

Pre-open indications: …. HOLD your cards (portfolio stocks) and see how the PLAY and 1 Puff/Pump/Promote

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are UP +0.95% (+296 points), S&P futures are UP +0.97% (+38 points) and NASDAQ futures are UP +0.79% (+93 points) early in the pre-open – so far,


Stock futures rose in the early pre-market, setting the pace for a positive open on Monday,

European stocks were higher,

Asia-Pacific stocks were mixed as global concerns continued to plague investors.



In Friday’s regular trading session, The Dow added +0.03% or 8.77 points after sinking as much as 600 points, the Nasdaq dropped -33.88 points or -0.30% lower; while the S&P 500 closed +0.57 points or + 0.01% higher after falling as much as 2.3% earlier in the session.

The S&P 500 has dropped about 18% this year through Friday, while the Dow has fallen 14% and the Nasdaq has tumbled around 27% <FactSet>.

Economic Data Docket: This coming week, investors will get fresh economic data on inflation, consumer spending and disposable income. The U.S. economic calendar also includes readings on consumer sentiment, U.S. manufacturing and services, initial jobless claims, and minutes from the Federal Open Market Committee’s last policy meeting.

Interesting Gene Therapy News: PTC Therapeutics (PTCT closed Friday +$1.42) is one step closer to getting its gene therapy approved in the EU. The European Medicines Agency announced earlier today that it would recommend granting a marketing authorization for the one-time gene therapy Upstaza, giving it the “exceptional circumstances” moniker.

  • Aromatic amino acid decarboxylase (AADC) deficiency is an ultra-rare genetic disease that leaves patients unable to produce certain hormones in the brain, such as dopamine and serotonin, usually leading to developmental delays, weak muscle tone and inability to control the movement of the limbs. It can also lead to multiple organ failure. To date, there have been no treatments approved for AADC deficiency, which has been identified in less than 150 patients. <Endpoint’s News>


RegMed Investors’ (RMi) closing bell: “from the precipice to the brink ending with a bridge to a positive close as confidence and conviction withers and regains as Pac-man algos munched away.” …

Ebb and flow –

Q2/22 –

May - 8 positive and 6 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


RegMed Investors (RMi) - Q1/22 Cell and Gene Therapy Earnings Scorecard Results … -- added Brainstorm Cell Therapeutics (BCLI), Homology Medicine FIXX) and Biostage (BSTG)


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

There are multiple indication but, how, many will play through on a positive upside moving session:

…. HOLD your cards (portfolio stocks) and see how the PLAY

Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed flat with 916 shares traded after Thursday’s +$0.63 with 916 shares traded, Wednesday’s +$0.10 with 980 shares traded after Tuesday’s -$0.89 and last Monday’s flat.

WARNING:  Earnings reported a VERY SAD picture of a company’s status without U.S investors and reliance on non-U.S. Chinese investors. Another PPM -private placement – this one for $5.1 M without a price per share notification. Also, the terminal death lawsuit just got settled (4/28) for $6 M with a PPM – a preferred convertible debt financing.  is it the ONLY avenue to finance utilizing non-U.S. Chinese investors?



The BOTTOM LINE: Three (3) positive closes (Friday, Thursday and Tuesday) could be a “set-up” for Monday’s  performance.

I am not always right but, more than frequently not wrong … I just DO NOT trust this market … too much fear and panic. This continuing state of volatility confirms fears that I have been expressing in these daily and weekly posts.

Again, as have I written (repeatedly), “There's a battle in the cell and gene therapy sector between which or what breaks first: share pricing resilience or tumbling into yet another downturn as fear remains beneath the strength of any positive close” …

I have NOT seen ANY step-up of declining company investment by ANY CEOs and their management teams – WHY NOT?

I try to keep it simple … and short!

I caution investors that the severe share pricing’s – technical and fundamental damage has been suffered these past several months which will take longer than a few good sessions to repair.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.